Type 2 diabetes / coronary artery disease Circulatory System
Conditions
Interventions
Meglitinide group: Repaglinide 6 mg daily, oral dose, during 1 week
Inhibitor DPP-4 group: Vildagliptin 100 mg daily, oral dose, during 1 week
Sponsors
Zerbini Foundation (Fundação Zerbini) (Brazil)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with type 2 diabetes mellitus under adequate drug treatment and no insulin dependence 2. A positive test for myocardial ischemia during a previous treadmill exercise test (horizontal or downsloping ST-segment depression >=1.0 mm) 3. Multivessel coronary disease confirmed by coronary angiography, and coronary disease with an internal diameter reduction of >=70% of at least two major coronary branches 4. Preserved left ventricular function confirmed by transthoracic echodopplercardiography
Exclusion criteria
Exclusion criteria: 1. Myocardial infarction during the last 3 month 2. Severely impaired myocardial function (ejection fraction <45%) 3. ECG changes that could interfere with the interpretation of the ST segment 4. Impaired hepatic or renal function 5. Progressive fatal disease 6. Mental disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will evaluate the effect of two hypoglycemic drugs on ischemic preconditioning by two sequential treadmill exercise tests (warm-up phenomenon). The warm-up phenomenon will be analysed by following parameters: 1. The time to onset of 1.0-mm ST-segment depression (the horizontal or downsloping ST-segment depressions were considered) 2. Rate pressure product (heart rate x systolic blood pressure) at the onset of 1.0-mm ST-segment depression | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
Brazil
Outcome results
None listed